Alnylam breaks ground on new manufacturing facility in Norton, Massachusetts

200,000 sq ft state-of-the-art biopharmaceutical manufacturing facility supports expanding development pipeline and transition toward commercial stage.

“This flagship multi-product facility represents a key next step in Alnylam’s transition toward a commercial stage company. Increased manufacturing capability is vital to support our rapidly growing pipeline of 10 clinical stage programs, two of which are in Phase III trials,” said John Maraganore, CEO of Alnylam. “The Massachusetts talent pool, along with strong support from state and local partners in the Baker Administration, Massachusetts Life Sciences Center, and the Town of Norton were critical to our ultimate decision to establish this manufacturing facility in Norton, MA.”

Speaking at the groundbreaking ceremony are Charlie Baker, the Governor of Massachusetts, Kimberly Haugstad, Executive Director of the Hemophilia Federation of America, Travis McCready, President and CEO of the Massachusetts Life Sciences Center and Lisa Nelson, Senior District Representative to US Congressman Joseph Kennedy III.

“Alnylam’s decision to locate their biopharmaceutical manufacturing facility in Massachusetts speaks to our Commonwealth’s success in supporting an innovative economic environment and talented workforce,” said Governor Charlie Baker. “We are excited about Alnylam’s choice and congratulate them as they continue to grow and advance investigational new medicines in the Commonwealth’s life sciences sector, creating new jobs and patient treatments.”

"The development of Alnylam’s manufacturing facility in Norton is further evidence that the State of Massachusetts can support the needs of integrated biotechnology companies such as Alnylam, through the entire biopharmaceutical life cycle, from discovery to development to manufacturing to sales and marketing,” said Travis McCready, President and CEO, Massachusetts Life Sciences Center.

“The Hemophilia Federation of America is dedicated to serving the needs of patients and families affected by hemophilia and other rare bleeding disorders,” said Kimberly Haugstad, Executive Director of the Hemophilia Federation of America. “With the development of this manufacturing facility, Alnylam demonstrates its commitment and responsibility to the patient community as it strives to provide innovative new treatment options.”